EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial

Zhihao Lu iD, Wenting Du, Xi Jiao, Yanni Wang, Jingwen Shi iD, Yang Shi, Yongqian Shu, Zuoxing Niu, Hiroki Hara iD, Jun Wu, Chih-Hung Hsu iD, Eric Van Cutsem iD und 6 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-01818 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Zhihao Lu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cance…. Hauptthemen laut MEDLINE: Receptor, Notch1, Esophageal Neoplasms, Antibodies, Monoclonal, Humanized, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Although multiple agents targeting PD-1 have been approved as second-line treatment for esophageal squamous cell carcinoma (ESCC), only a fraction of patients derive long-term survival. Hence, reliable predictive biomarkers are urgently needed. METHODS Comprehensive tumor genomic profiling and transcriptome sequencing were performed on samples from the RATIONALE-302 study. We also conducted single-cell RNA sequencing analysis on Notch1 knockdown ESCC murine models to further explore the potential molecular mechanisms underlying anti–PD-1 benefit. RESULTS We identified NOTCH1 mutation as a potential predictive biomarker for longer overall survival (OS) with tislelizumab versus chemotherapy (18.4 months v 5.3 months; hazard ratio, 0.35 [95% CI, 0.17 to 0.71]). At the transcriptional level, type I IFN (IFN-I)/toll-like receptor expression signatures were positively associated with OS benefit of tislelizumab, whereas B-cell and neutrophil signatures predicted unfavorable OS. Exploratory analyses showed that the presence of NOTCH1 mutation correlated with enrichment of IFN-I signatures and reduced infiltration of B cells and neutrophils. In murine models, comparative single-cell transcriptome analyses further revealed that Notch1 deficiency facilitated a more immunologically activated tumor microenvironment which potentiated anti–PD-1 treatment. CONCLUSION Our data provide novel insights for anti–PD-1 treatment selection using NOTCH1 mutations and may provide a rationale for combination therapy in ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Notch1Esophageal NeoplasmsAntibodies, Monoclonal, HumanizedEsophageal Squamous Cell CarcinomaMutationBiomarkers, TumorHumansAnimalsMiceFemaleMaleMiddle AgedSurvival Analysis

Substanzen

Receptor, Notch1Antibodies, Monoclonal, HumanizedNOTCH1 protein, humanBiomarkers, Tumortislelizumab

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Clinical Biomarker, BeiGene (Shanghai) Co, Ltd, Shanghai, China.
  • Clinical Biomarker, BeiGene (Beijing) Co, Ltd, Beijing, China.
  • The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)-Cancer Center, Nanjing, China.
  • Shandong Cancer Hospital-Oncology, Jinan, China.
  • Saitama Cancer Center-Gastroenterology, Kitaadachi-gun, Japan.

ORCID-Profile: Zhihao Lu, Jingwen Shi, Hiroki Hara, Chih-Hung Hsu, Eric Van Cutsem, Lin Shen

Zitieren

APA

Lu, Z., Du, W., Jiao, X., Wang, Y., Shi, J., Shi, Y., Shu, Y., Niu, Z., Hara, H., Wu, J., Hsu, C. H., Van Cutsem, E., Brock, M. V., Zhang, Z., Ding, N., Zhang, Y., Shen, Z., & Shen, L. (2025). NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01818

Vancouver

Lu Z, Du W, Jiao X, Wang Y, Shi J, Shi Y, et al. NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01818

BibTeX
@article{Lu2025,
  author = {Lu, Zhihao and Du, Wenting and Jiao, Xi and Wang, Yanni and Shi, Jingwen and Shi, Yang and Shu, Yongqian and Niu, Zuoxing and Hara, Hiroki and Wu, Jun and Hsu, Chih-Hung and Van Cutsem, Eric and Brock, Malcolm V and Zhang, Zhang and Ding, Ningning and Zhang, Yun and Shen, Zhirong and Shen, Lin},
  title = {NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-01818}
}
Kostenlos starten →